FDA Oncology Announcements

Announcements Trials

Somatostatin analog × Clear all

Conditions

Drug Classes

Anti-PD-1 109 Anti-PD-L1 33 Anti-CD20 25 Immunomodulatory drugs (IMiDs) 23 PARP inhibitor 21 Platinum agent 21 Anti-CD38 20 Taxane 20 VEGFR inhibitor 20 Anti-VEGFR 19 BTK inhibitor 19 Anti-HER2 18 BRAF inhibitor 18 Bcr-Abl inhibitor 18 EGFR inhibitor 18 Proteasome inhibitor 18 Anti-CTLA-4 17 ALK inhibitor 15 Anti-CD19 CAR T-cell 15 MEK inhibitor 15 Anti-EGFR 13 RET inhibitor 12 MTOR inhibitor 11 Anti-HER2 ADC 10 CDK inhibitor 10 ERBB2 inhibitor 10 Second-generation nonsteroidal antiandrogen 10 Antifolate 9 Multikinase inhibitor 9 Nitrogen mustard 9 Pyrimidine analog 9 Alkylating agent 8 DNA methyltransferase inhibitor 8 Fluoropyrimidine 8 IDH inhibitor 8 Anti-CD30 ADC 7 Bcl-2 inhibitor 7 Estrogen receptor inhibitor 7 FGFR inhibitor 7 Megakaryocyte growth factor 7 Anthracycline 5 Anti-CD20-CD3 bispecific 5 Anti-EGFR-HGFR bispecific 5 Anti-TACSTD2 ADC 5 Anti-nectin-4 ADC 5 Asparagine-specific enzyme 5 JAK inhibitor 5 MET inhibitor 5 PDGFR inhibitor 5 Radioactive agent 5 XPO1 inhibitor 5 Anti-BCMA-CD3 bispecific 4 Anti-CD19-CD3 bispecific 4 EZH inhibitor 4 HDAC inhibitor 4 KRAS inhibitor 4 Multi-ingredient 4 PI3K delta inhibitor 4 Anti-BCMA ADC 3 Anti-CD19 3 Anti-CD33 ADC 3 Anti-GD2 3 Anti-RANKL 3 CYP17 inhibitor 3 FLT3 inhibitor 3 GnRH antagonist 3 HIF-2a inhibitor 3 KMT2A inhibitor 3 Non-taxane microtubule dynamics inhibitor 3 PI3K alpha inhibitor 3 ROS1 inhibitor 3 TGF-beta inhibitor 3 TRK inhibitor 3 Topoisomerase I inhibitor 3 Topoisomerase II inhibitor 3 AKT1 inhibitor 2 Anti-BCMA CAR T-cell 2 Anti-CD22 ADC 2 Anti-CD79B ADC 2 Anti-DLL3-CD3 bispecific 2 Anti-FOLR1 ADC 2 Anti-TF ADC 2 Anti-TROP2 ADC 2 Aromatase inhibitor third generation 2 Erythrocyte growth factor 2 Factor IXa/Xa bridging 2 Granulocyte colony-stimulating factor 2 Low molecular weight heparin 2 Purine analog 2 SMO inhibitor 2 STAMP inhibitor 2 Adenovirus vector 1 Anti-C5 1 Anti-CCR4 1 Anti-CD19 ADC 1 Anti-CD22 immunotoxin 1 Anti-CLDN18.2 1 Anti-CSF1R 1 Anti-GPRC5D-CD3 bispecific 1 Anti-HER2 bispecific 1 Anti-HER2-HER3 bispecific 1 Anti-IFNg 1 Anti-IL-2R immunotoxin 1 Anti-IL-6 1 Anti-MAGE-A4 SPEAR T-cell 1 Anti-P-selectin 1 Anti-PDGFR 1 Anti-SLAMF7 1 Anti-c-Met ADC 1 Anti-dabigatran antibody fragment 1 Anti-vWF 1 Antimetabolite 1 Bispecific gp100 peptide-HLA-directed CD3 T-cell engager 1 CSF1R inhibitor 1 CXCR4 inhibitor 1 Cellular therapy 1 Chemotherapy protective agent 1 EDTA derivative 1 Factor Xa inhibitor 1 Gamma secretase inhibitor 1 Hedgehog pathway inhibitor 1 Hemoglobin S polymerization inhibitor 1 IL-15 receptor alpha fusion protein 1 IL-3 fused immunotoxin 1 Interferon 1 Iron chelating agent 1 Mononuclear cell vaccine 1 Oncolytic viral therapy 1 Ornithine decarboxylase inhibitor 1 Peptidase-enhanced nitrogen mustard 1 Profibrinolytic 1 ROCK2 inhibitor 1 Replacement therapy 1 SYK inhibitor 1 Selective estrogen receptor modulator 1 Somatostatin analog 1 Telomerase inhibitor 1 Triazene 1 Vinca alkaloid 1

1 Announcement

Lanreotide

Drug: Somatuline Depot (lanreotide) · Somatostatin analog
Conditions: EndocrineNET

Data powered by HemOnc (CC BY 4.0) Colophon ⚡